Navigation Links
Bone-Strengthening Drug Guards Against Spread of Breast Cancer

Zoledronic acid protected against chemotherapy-related bone loss, metastasis, study finds

WEDNESDAY, March 31 (HealthDay News) -- The bone-strengthening drug zoledronic acid (Zometa) reduces the spread of breast cancer by preventing chemotherapy-related bone loss, a new study suggests.

Tumor cells released from the primary breast cancer site often travel to the bone marrow and spread from there to other areas of the body. Chemotherapy speeds up bone turnover, which releases bone-derived growth factors that can promote tumor growth in breast cancer patients.

It's been suggested that zoledronic acid -- which reduces bone loss by slowing the activity of cells that destroy bone -- can make bone marrow a less inviting place for cancer cells.

The new phase 2 trial included 120 women undergoing chemotherapy for locally advanced breast cancer. Some of the patients received 4 milligrams of zoledronic acid every three weeks for one year starting with their first dose of chemotherapy, while others received no zoledronic acid.

Bone marrow samples were taken at the start of the study and again after three months and one year of treatment. At the start of the study, 45.7 percent of patients had detectable tumor cells in their bone marrow. After three months of treatment, women who received zoledronic acid and chemotherapy had fewer detectable tumor cells than those who received chemotherapy alone, according to Rebecca Aft, of the Washington University School of Medicine in St. Louis, and colleagues.

Among women who had no tumor cells in their bone marrow at the start of the study, 87 percent of those in the zoledronic acid group were free of tumor cells at three months, compared with 60 percent of those who received chemotherapy alone. One year after treatment, the rates were 40 percent and 33 percent, respectively, the study authors noted.

The researchers also found that zoledronic acid prevented chemotherapy-related bone loss. Among patients who had low bone mineral density at the start of the study, 44 percent of those who took zoledronic acid had normal bone density after one year and significant decreases in bone-turnover markers at three months and one year.

The study, which appears online March 31 in The Lancet Oncology, was funded by Novartis Pharmaceuticals and Pfizer Inc.

More information

The U.S. National Cancer Institute has more about breast cancer treatments.

-- Robert Preidt

SOURCE: The Lancet Oncology, news release, March 31, 2010

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Educates Homeowners on Lead Poisoning Safeguards During National Poison Prevention Week
2. Vitamin D Plus Calcium Guards Against Fractures
3. Exercise Guards White Blood Cells Against Aging
4. Research confirms that some forms of massage help against low-back pain
5. Study finds surgical masks provided effective protection of health-care workers against H1N1
6. IPhone App is New Tool in the Fight Against Breast Cancer
7. Food Safety Attorney Fred Pritzker Calls for Criminal Sanctions Against Food Poisoners
8. Motherhood a Buffer Against Suicide
9. State Legislators Last Line of Defense Against ObamaCare
10. Poorly understood cell plays role in immunity against the flu
11. Study Details Machinery of Immune Protection Against Inflammatory Diseases Like Colitis
Post Your Comments:
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
Breaking Medicine Technology: